Current Research in Drug Discovery

Associate Editors

  • Levente Karpati
    Semmelweis University, Faculty of Pharmacology
    Hungary
  • Jan Eickhoff
    Dortmund GmbH, Head of Assay Development and Screening, Hit Discovery Constance GmbH, Managing Director
    Germany
    Expertise: Chemical Biology, Medicinal Chemistry, Biochemistry
  • Hongtao Lu
    Vice President & Chief Scientific Officer, Zai Laboratory Inc.
    China
    Expertise: Target identification and validation, biomarker discovery, cell-based assay, phenotypic screening, T cell subset differentiation, inflammatory diseases and neurodegenrative diseases.

Editorial Board Members

  • Andy Zayenga
    Managing Director, SmarterLab - Laboratory Automation Consulting
    United States
    Expertise: Laboratory automation, compound management, high throughput screening, drug discovery, assay development, screening technologies, liquid handling, microfluidics, biobanking, biorepository automation, biostorage and environmental repository operation, business development, process analysis and recommendation, system integration and implementation, project management.
  • David John Hayes
    AstraZeneca
    United States
    Expertise: Drug discovery, assay development, enzymology, HTS, biomarker discovery, immuno-assay, multiplex technologies, label-free technologies, protein biochemistry, toxicity, cell based assays, kinases, proteases
  • Krishna P Kota
    United States Army Medical Institute of Infectious Diseases
    United States
    Expertise: Cell based assay, High Content Screening, High Throughput Screening, Proteomics
  • Matt Boeckeler
    Automation & Research Technologies Team Chair, AstraZeneca
    United States
    Expertise: Compound Management, high throughput screening, biobanking, assay development, laboratory automation development and implementation, laboratory information systems, value chain optimization and operations, change management leadership, cross-functional team building, process improvement
  • Rathnam Chaguturu
    Founder and CEO, iDDPartners
    United States
    Expertise: Target identification-validation, high throughput screening, pharmacology, PK/PD, ADME.
  • Sheraz Gul
    University of California
    United States
    Expertise: Assay development, high throughput screening, enzymology, biochemical assays, cell-based assays, drug discovery, high content analysis, data mining, biomarkers discovery, ADME, microfluidics, sample management, cell based assay, 3D cell culture.
  • Timothy Dawes
    Sr. Scientific Manager, Genentech Inc
    United States
    Expertise: Screening technologies, laboratory automation, high throughput screening, assay development and validation, data mining, microfluidics, sample management, cell based assays and biobanking.
  • David Tattersall
    Director Parkinson’s Disease Group Neurodegeneration DPU, GlaxoSmithKline.
    United Kingdom
    Expertise: Target and lead identification and validation, biomarkers discovery, biobanking, phenotypic screening
  • Davide Gianni
    Team Leader
    Innovative Medicines and Early Development
    Discovery Sciences - Cellular Assay Development
    Astrazeneca
    United Kingdom
    Expertise: Target and lead identification and validation, biomarkers discovery, cell based assay, assay development and validation
  • Gael Hédou
    Neurosciences Centre of Excellence for Drug Discovery
    United Kingdom
    Expertise: target and lead identification and validation, biomarkers discovery, ADME, pharmacology, in vivo pharmacology, preclinical experimental design, lean drug discovery and development, compoound selection and optimization
  • Jonathan Wingfield
    University of Wales
    United Kingdom
    Expertise: Assay development, laboratory automation, high content imaging, mass spectrometry, LIMS.
  • Juan Manuel Dominguez
    PharmaMar
    Spain
    Expertise: enzymology, protein biochemistry, assay development and validation, mode of action studies.
  • Paul Andrews
    Stem Cell Solutions Ltd
    Scotland
    Expertise: Screening technologies, target identification and validation, laboratory automation, assay development and validation, high content analysis, data mining, biomarkers discovery, biobanking, cell based assays, use of stem cells in drug discovery, iPS-disease modelling, phenotypic screening
  • Tsutomu Kamiyama
    General Manager of Discovery Screening, Mitsubishi Tanabe Pharma Corporation
    Japan
    Expertise: small molecule drug discovery, high throughput screening, screening technologies, lead identification and validation, laboratory automation, ADMET-HTS, sample management and natural products screening
  • Luigi Formisano
    Unisannio Univ, Benevento
    Italy
    Expertise: Cell Based Assay, Cell Culture, Miscroscopy, Flow Cytometry, Cell Biology, Pharmacology, Toxicology, Molecular Biology, Protein Biochemistry, Protein-Protein Interaction, Epigenetic and Neurodegenerative Diseases
  • Leonardo J. Solmesky
    Kadimastem Ltd.
    Israel
    Expertise: Laboratory automation, assay development and validation, high content analysis, biomarkers discovery, cell based assay, phenotypic screening, facility management, and personalized drug discovery
  • Pratima Srivastava
    Associate Director Biology, GVK Biosciences
    India
    Expertise: Drug metabolism and pharmacokinetics, pharmacogenomics, pharmacology, toxicology, molecular biology.
  • Sanjeev Saxena
    Senior Research Scientist, Orchid Chemicals & Pharmaceuticals Ltd
    India
    Expertise: Target and lead identification and validation, in vitro and in vivo pharmacology, disease models, biomarker discovery.
  • Rodolphe Hajj
    Pharnext
    France
    Expertise: Target identification and validation, assay development and validation, high content analysis and screening, biomarkers discovery, biobanking, cell based assay, cell culture, miscroscopy, flow cytometry, stem cells.
  • Luigi Piero Stasi
    Nuevolution
    Denmark
    Expertise: Medicinal chemistry, lead identification, ADME, CNS.
  • Ming Qiang Zhang
    Vice President & Head Research & Development China, Amgen Inc.
    China
    Expertise: Medicinal chemistry of antiviral, anticancer, anti-inflammatory/anti-allergic, CNS, agents, Heterocyclic, neucleside/tides, carbohydrate, national products / macrocycles, supramolecular / host-guest chemistry, Biomarker, patient stratification, clinical trials and regulatory
  • Qiyue Hu
    Associate Director, Shanghai Hengrui Pharmaceutical Co.
    China
    Expertise: Computational chemistry, cheminformatics, structure-based drug discovery, ligand-based drug design, bioinformatics, virtual Screening, hit-to-lead, medicinal chemistry, antibody modeling, protein design.
  • Raymond Zhao
    Neuroscience Therapeutic Area Unit, GlaxoSmithKline
    China
    Expertise: Screening technologies, target and lead identification and validation, laboratory automation, assay development and validation, biomarkers discovery, ADME, BioMEMS, Phenotypic screening.
  • Tiziana Adage
    BIT Pharma GmbH
    Austria
    Expertise: Non-clinical and early clinical pharmacology in the areas of inflammatory and autoimmune diseases, diabetes type 1 and type 2, obesity, neurodegeneration, neuropsychopharmacology, oncology, respiratory diseases and in vivo phenotyping screening. In vitro pharmacology, assay development and validation, bioanalytics, biomarker discovery and translational medicine.

Past Editors

  • Giancarlo Basile
    Editor in Chief
    Jan, 2014 - Jun, 2015